ZYDUS PHARMS USA
GenericsZYDUS PHARMS USA is a generic drug manufacturer focused on Neurology, Cardiovascular, Infectious Disease.
ZYDUS PHARMS USA at a Glance
- Growing R&D activity with 5 trials in last 2 years
- Fast trial execution (32 months median completion)
ZYDUS PHARMS USA's Key Drugs
ZYDUS PHARMS USA's core commercial portfolio centers on IRBESARTAN; HYDROCHLOROTHIAZIDE, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
ZYDUS PHARMS USA's Recent FDA Approvals
New NDA/BLA approvals for ZYDUS PHARMS USA over the last two years — novel drugs only, excluding generics and label supplements.
ZYDUS PHARMS USA's Therapeutic Areas
ZYDUS PHARMS USA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZYDUS PHARMS USA's Top Competitors
ZYDUS PHARMS USA's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and WARNER CHILCOTT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZYDUS PHARMS USA Pipeline Snapshot
Active clinical trials for ZYDUS PHARMS USA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IRBESARTAN; HYDROCHLOROTHIAZIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/3 completed
- • Speed: 32 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2005-01-28
- Latest
- 2026-06-18
- Applications
- 81
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges